Delayed Denosumab Injections and Fracture Risk Among Patients With Osteoporosis

Study (n=2,594) reports although delayed administration of subsequent denosumab doses by > 16 weeks was linked to increased risk for vertebral fracture vs. on-time dosing (HR 3.91; 95% CI, 1.62-9.45); evidence is insufficient to conclude increased fracture risk is at other sites


Annals of Internal Medicine